Effects of early carvedilol treatment and withdrawal on the development of hypertension and renal vascular narrowing

Michelle M. Kett, Kate M. Denton, Erika I Boesen, Warwick P. Anderson

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Background: The aims of this study were to examine whether combined blockade of α1 and β-adrenoceptors with carvedilol postweaning affected the development of hypertension and renal vascular narrowing in spontaneously hypertensive rats (SHR), and whether these effects on pressure and renal vascular changes persisted after treatment withdrawal. Methods: From 4 to 12 weeks of age male SHR were administered carvedilol in rat chow at 1.2 mg/g chow (low-dose) or 2.4 mg/g chow (high-dose), or were given normal chow. At 12 weeks of age, rats from each group either underwent experimentation or had treatment withdrawn and were studied at 20 weeks. On the experimental day, conscious mean arterial pressure (MAP) was measured and, as a functional test of renal vessel lumen characteristics, pressure-flow and pressure-glomerular filtration rate (pressure-GFR) relationships were determined in the maximally dilated kidney. Results: At 12 weeks of age, SHR on low and high-dose carvedilol had significantly lower MAP than that of untreated SHR (137 ± 3, 134 ± 1, 152 ± 2 mm Hg, respectively; P < .001). The SHR treated with high-dose (but not low-dose) carvedilol demonstrated a steeper renal pressure-flow relationship (P < .001), and a leftward shifted (P < .01) and steeper (P < .001) pressure-GFR relationship compared with control SHR. Eight weeks after carvedilol withdrawal, there were no significant differences in MAP, pressure-flow, or pressure-GFR relationships between groups. Conclusions: These results suggest that postweaning α1 and β-adrenoceptor blockade with high-dose carvedilol attenuated the development of hypertension and led to a preferential reduction in preglomerular resistance (increased lumen dimensions) independent of the effects on MAP. However, treatment of SHR from 4 to 12 weeks of age with high-dose carvedilol did not lead to persistent, long-term effects on arterial pressure or renal vascular narrowing after treatment withdrawal.

Original languageEnglish (US)
Pages (from-to)161-166
Number of pages6
JournalAmerican Journal of Hypertension
Volume17
Issue number2
DOIs
StatePublished - Jan 1 2004

Fingerprint

Renal Hypertension
Inbred SHR Rats
Blood Vessels
Pressure
Arterial Pressure
Kidney
Glomerular Filtration Rate
Adrenergic Receptors
carvedilol
Hypertension

Keywords

  • Hypertension
  • Sympathetic nervous system
  • Vascular remodeling
  • α -adrenoceptor
  • β-adrenoceptor

ASJC Scopus subject areas

  • Internal Medicine

Cite this

Effects of early carvedilol treatment and withdrawal on the development of hypertension and renal vascular narrowing. / Kett, Michelle M.; Denton, Kate M.; Boesen, Erika I; Anderson, Warwick P.

In: American Journal of Hypertension, Vol. 17, No. 2, 01.01.2004, p. 161-166.

Research output: Contribution to journalArticle

@article{79318616582e47818634486d46d42e86,
title = "Effects of early carvedilol treatment and withdrawal on the development of hypertension and renal vascular narrowing",
abstract = "Background: The aims of this study were to examine whether combined blockade of α1 and β-adrenoceptors with carvedilol postweaning affected the development of hypertension and renal vascular narrowing in spontaneously hypertensive rats (SHR), and whether these effects on pressure and renal vascular changes persisted after treatment withdrawal. Methods: From 4 to 12 weeks of age male SHR were administered carvedilol in rat chow at 1.2 mg/g chow (low-dose) or 2.4 mg/g chow (high-dose), or were given normal chow. At 12 weeks of age, rats from each group either underwent experimentation or had treatment withdrawn and were studied at 20 weeks. On the experimental day, conscious mean arterial pressure (MAP) was measured and, as a functional test of renal vessel lumen characteristics, pressure-flow and pressure-glomerular filtration rate (pressure-GFR) relationships were determined in the maximally dilated kidney. Results: At 12 weeks of age, SHR on low and high-dose carvedilol had significantly lower MAP than that of untreated SHR (137 ± 3, 134 ± 1, 152 ± 2 mm Hg, respectively; P < .001). The SHR treated with high-dose (but not low-dose) carvedilol demonstrated a steeper renal pressure-flow relationship (P < .001), and a leftward shifted (P < .01) and steeper (P < .001) pressure-GFR relationship compared with control SHR. Eight weeks after carvedilol withdrawal, there were no significant differences in MAP, pressure-flow, or pressure-GFR relationships between groups. Conclusions: These results suggest that postweaning α1 and β-adrenoceptor blockade with high-dose carvedilol attenuated the development of hypertension and led to a preferential reduction in preglomerular resistance (increased lumen dimensions) independent of the effects on MAP. However, treatment of SHR from 4 to 12 weeks of age with high-dose carvedilol did not lead to persistent, long-term effects on arterial pressure or renal vascular narrowing after treatment withdrawal.",
keywords = "Hypertension, Sympathetic nervous system, Vascular remodeling, α -adrenoceptor, β-adrenoceptor",
author = "Kett, {Michelle M.} and Denton, {Kate M.} and Boesen, {Erika I} and Anderson, {Warwick P.}",
year = "2004",
month = "1",
day = "1",
doi = "10.1016/j.amjhyper.2003.09.013",
language = "English (US)",
volume = "17",
pages = "161--166",
journal = "American Journal of Hypertension",
issn = "0895-7061",
publisher = "Oxford University Press",
number = "2",

}

TY - JOUR

T1 - Effects of early carvedilol treatment and withdrawal on the development of hypertension and renal vascular narrowing

AU - Kett, Michelle M.

AU - Denton, Kate M.

AU - Boesen, Erika I

AU - Anderson, Warwick P.

PY - 2004/1/1

Y1 - 2004/1/1

N2 - Background: The aims of this study were to examine whether combined blockade of α1 and β-adrenoceptors with carvedilol postweaning affected the development of hypertension and renal vascular narrowing in spontaneously hypertensive rats (SHR), and whether these effects on pressure and renal vascular changes persisted after treatment withdrawal. Methods: From 4 to 12 weeks of age male SHR were administered carvedilol in rat chow at 1.2 mg/g chow (low-dose) or 2.4 mg/g chow (high-dose), or were given normal chow. At 12 weeks of age, rats from each group either underwent experimentation or had treatment withdrawn and were studied at 20 weeks. On the experimental day, conscious mean arterial pressure (MAP) was measured and, as a functional test of renal vessel lumen characteristics, pressure-flow and pressure-glomerular filtration rate (pressure-GFR) relationships were determined in the maximally dilated kidney. Results: At 12 weeks of age, SHR on low and high-dose carvedilol had significantly lower MAP than that of untreated SHR (137 ± 3, 134 ± 1, 152 ± 2 mm Hg, respectively; P < .001). The SHR treated with high-dose (but not low-dose) carvedilol demonstrated a steeper renal pressure-flow relationship (P < .001), and a leftward shifted (P < .01) and steeper (P < .001) pressure-GFR relationship compared with control SHR. Eight weeks after carvedilol withdrawal, there were no significant differences in MAP, pressure-flow, or pressure-GFR relationships between groups. Conclusions: These results suggest that postweaning α1 and β-adrenoceptor blockade with high-dose carvedilol attenuated the development of hypertension and led to a preferential reduction in preglomerular resistance (increased lumen dimensions) independent of the effects on MAP. However, treatment of SHR from 4 to 12 weeks of age with high-dose carvedilol did not lead to persistent, long-term effects on arterial pressure or renal vascular narrowing after treatment withdrawal.

AB - Background: The aims of this study were to examine whether combined blockade of α1 and β-adrenoceptors with carvedilol postweaning affected the development of hypertension and renal vascular narrowing in spontaneously hypertensive rats (SHR), and whether these effects on pressure and renal vascular changes persisted after treatment withdrawal. Methods: From 4 to 12 weeks of age male SHR were administered carvedilol in rat chow at 1.2 mg/g chow (low-dose) or 2.4 mg/g chow (high-dose), or were given normal chow. At 12 weeks of age, rats from each group either underwent experimentation or had treatment withdrawn and were studied at 20 weeks. On the experimental day, conscious mean arterial pressure (MAP) was measured and, as a functional test of renal vessel lumen characteristics, pressure-flow and pressure-glomerular filtration rate (pressure-GFR) relationships were determined in the maximally dilated kidney. Results: At 12 weeks of age, SHR on low and high-dose carvedilol had significantly lower MAP than that of untreated SHR (137 ± 3, 134 ± 1, 152 ± 2 mm Hg, respectively; P < .001). The SHR treated with high-dose (but not low-dose) carvedilol demonstrated a steeper renal pressure-flow relationship (P < .001), and a leftward shifted (P < .01) and steeper (P < .001) pressure-GFR relationship compared with control SHR. Eight weeks after carvedilol withdrawal, there were no significant differences in MAP, pressure-flow, or pressure-GFR relationships between groups. Conclusions: These results suggest that postweaning α1 and β-adrenoceptor blockade with high-dose carvedilol attenuated the development of hypertension and led to a preferential reduction in preglomerular resistance (increased lumen dimensions) independent of the effects on MAP. However, treatment of SHR from 4 to 12 weeks of age with high-dose carvedilol did not lead to persistent, long-term effects on arterial pressure or renal vascular narrowing after treatment withdrawal.

KW - Hypertension

KW - Sympathetic nervous system

KW - Vascular remodeling

KW - α -adrenoceptor

KW - β-adrenoceptor

UR - http://www.scopus.com/inward/record.url?scp=1642452755&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1642452755&partnerID=8YFLogxK

U2 - 10.1016/j.amjhyper.2003.09.013

DO - 10.1016/j.amjhyper.2003.09.013

M3 - Article

VL - 17

SP - 161

EP - 166

JO - American Journal of Hypertension

JF - American Journal of Hypertension

SN - 0895-7061

IS - 2

ER -